Literature DB >> 17552015

Study of the expressions of p53 and bcl-2 genes, the telomerase activity and apoptosis in GIST patients.

Qiang Wang1, You-Wei Kou.   

Abstract

AIM: To explore the relationship between clinicobiological behavior and the expression levels of telomerase activity, apoptosis, p53 gene and bcl-2 gene in gastrointestinal stromal tumors (GISTs).
METHODS: The intensity of telomerase activity, apoptosis, p53 and bcl-2 expression in GISTs were detected by telomeric repeat amplification protocol, in situ end-labeling technique, and immunohistochemistry, respectively.
RESULTS: The positive rates of telomerase activity of malignant GIST, potential malignant GIST and benign GIST were 85% (17/20), 22.8% (2/9) and 0 (0/9), respectively. The apoptosis indices of malignant GIST, potential malignant GIST, and benign GIST were 11.7 +/- 5.4, 30.2 +/- 5.6 and 45.2 +/- 7.2, respectively. The intensity of telomerase activity and apoptosis were related to the biological characteristics of GISTs (85% vs 22.8%, 0, 0; P < 0.01 or 11.7 +/- 5.4 vs 30.2 +/- 5.6, 45.2 +/- 7.2, 72.1 +/- 9.3; P < 0.05). The intensity of telomerase activity was negatively correlated with cellular apoptosis (22.9 +/- 8.4 vs 9.5 +/- 5.7, P < 0.01). The intensity of telomerase activity was positively correlated with p53, bcl-2 expression (40.0% vs 78.9%, 40.0% vs 84.2%; P < 0.05).
CONCLUSION: The detection of telomerase activity, apoptosis and its control genes in GIST will be helpful for the discrimination of the malignant and benign GIST and evaluation of the prognosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17552015      PMCID: PMC4146828          DOI: 10.3748/wjg.v13.i18.2626

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  16 in total

Review 1.  Life and cancer without telomerase.

Authors:  V A Zakian
Journal:  Cell       Date:  1997-10-03       Impact factor: 41.582

Review 2.  A survey of telomerase activity in human cancer.

Authors:  J W Shay; S Bacchetti
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

Review 3.  Telomeres and telomerase: biological and clinical importance.

Authors:  R Dahse; W Fiedler; G Ernst
Journal:  Clin Chem       Date:  1997-05       Impact factor: 8.327

4.  Bcl-2 modulates telomerase activity.

Authors:  M Mandal; R Kumar
Journal:  J Biol Chem       Date:  1997-05-30       Impact factor: 5.157

5.  Alteration of telomerase activity associated with development and extension of epithelial ovarian cancer.

Authors:  T Oishi; J Kigawa; Y Minagawa; M Shimada; M Takahashi; N Terakawa
Journal:  Obstet Gynecol       Date:  1998-04       Impact factor: 7.661

Review 6.  Clinical implications of telomerase in cancer.

Authors:  N W Kim
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

7.  Telomerase activity of sarcoma cell lines and fibroblasts is independent of p53 status.

Authors:  M Milas; D Yu; D Sun; R E Pollock
Journal:  Clin Cancer Res       Date:  1998-06       Impact factor: 12.531

8.  Gastric stromal tumors. Reappraisal of histogenesis.

Authors:  M T Mazur; H B Clark
Journal:  Am J Surg Pathol       Date:  1983-09       Impact factor: 6.394

9.  Experimental elongation of telomeres extends the lifespan of immortal x normal cell hybrids.

Authors:  W E Wright; D Brasiskyte; M A Piatyszek; J W Shay
Journal:  EMBO J       Date:  1996-04-01       Impact factor: 11.598

10.  Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.

Authors:  Y Gavrieli; Y Sherman; S A Ben-Sasson
Journal:  J Cell Biol       Date:  1992-11       Impact factor: 10.539

View more
  6 in total

Review 1.  Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis.

Authors:  Gloria Ravegnini; Giulia Sammarini; Margherita Nannini; Maria A Pantaleo; Guido Biasco; Patrizia Hrelia; Sabrina Angelini
Journal:  Autophagy       Date:  2017-01-05       Impact factor: 16.016

2.  Synchronous adenocarcinoma and gastrointestinal stromal tumors in the stomach.

Authors:  Rong Cai; Gang Ren; Deng-Bin Wang
Journal:  World J Gastroenterol       Date:  2013-05-28       Impact factor: 5.742

3.  Low frequency of TERT promoter mutations in gastrointestinal stromal tumors (GISTs).

Authors:  Nathália C Campanella; Ricardo Celestino; Ana Pestana; Cristovam Scapulatempo-Neto; Antonio Talvane de Oliveira; Maria José Brito; António Gouveia; José Manuel Lopes; Denise Peixoto Guimarães; Paula Soares; Rui M Reis
Journal:  Eur J Hum Genet       Date:  2014-09-24       Impact factor: 4.246

4.  TERT promoter mutations are a rare event in gastrointestinal stromal tumors.

Authors:  Keisuke Akaike; Midori Toda-Ishii; Yoshiyuki Suehara; Kenta Mukaihara; Daisuke Kubota; Keiko Mitani; Tatsuya Takagi; Kazuo Kaneko; Takashi Yao; Tsuyoshi Saito
Journal:  Springerplus       Date:  2015-12-30

5.  Inhibition of stromal-interacting molecule 1-mediated store-operated Ca2+ entry as a novel strategy for the treatment of acquired imatinib-resistant gastrointestinal stromal tumors.

Authors:  Ziyi Yang; Lijia Pan; Shilei Liu; Fengnan Li; Wenjie Lv; Yijun Shu; Ping Dong
Journal:  Cancer Sci       Date:  2018-07-28       Impact factor: 6.716

6.  Clinicopathological and molecular characteristics of synchronous gastric adenocarcinoma and gastrointestinal stromal tumors.

Authors:  Jun-Ming Luo; Fa-Long Cao; Chen Meng; Li-Jun Lin; Si-Qing Ma; Shao-Hua Peng; Hong-Ling Gao; Sara Javidiparsijani; Gui-Rong Wang; Meng-Lan Zhang; Jian-Guo Xin; Yi-Chun Wang; Shu-Kun Zhang
Journal:  Sci Rep       Date:  2017-10-10       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.